Paper Details

  1. Home
  2. Paper Details

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Author: , BonnefoiHervé, ChirgwinJacquie, CoatesAlan S, EjlertsenBent, GoldhirschAron, PriceKaren N, ReganMeredith M, SmithIan, SunZhuoxin, ThürlimannBeat

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Letrozole, an aromatase inhibitor, is effective in postmenopausal women but may be less beneficial in certain subpopulations with potential residual ovarian activity. This study analyzed data from the BIG 1-98 trial, focusing on younger women with natural menopause and those with chemotherapy-induced menopause. Contrary to initial concerns, the findings suggest that letrozole remains an effective treatment option even in these subpopulations.
Paper Details　
Original Abstract of the Article :
Letrozole, an aromatase inhibitor, is ineffective in the presence of ovarian estrogen production. Two subpopulations of apparently postmenopausal women might derive reduced benefit from letrozole due to residual or returning ovarian activity: younger women (who have the potential for residual subcli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/21892704

データ提供：米国国立医学図書館（NLM）

Letrozole vs. Tamoxifen: A Battle for Breast Cancer Treatment

The world of breast cancer treatment is a vast desert, full of challenges and uncertainties. Researchers are constantly searching for new oases of knowledge to guide their decisions. One such oasis is the BIG 1-98 trial, which investigated the effectiveness of letrozole, an aromatase inhibitor, compared to tamoxifen, a selective estrogen receptor modulator, in postmenopausal women with early breast cancer.

This study examined two particular subpopulations: younger women with natural menopause and those with chemotherapy-induced menopause. The researchers were curious to see if these women might benefit less from letrozole due to potential residual or returning ovarian estrogen production. To their surprise, both groups showed a similar disease-free survival benefit from letrozole as the overall trial population.

Aray of Hope for Younger Women

This study offers a beacon of hope for younger women, showing that letrozole remains a viable treatment option, even in those who might have some residual ovarian activity. It's a testament to the incredible progress we've made in understanding and treating breast cancer.

Letrozole: A New Oasis in the Desert

This study provides valuable insight into the effectiveness of letrozole in specific subpopulations of postmenopausal women. It suggests that letrozole can be a valuable treatment option, even for those with some residual ovarian activity, offering hope for a better future for those battling breast cancer.

Dr.Camel's Conclusion

This study, like a refreshing oasis in the desert, provides valuable insights into the effectiveness of letrozole, even in younger postmenopausal women and those with chemotherapy-induced menopause. While the desert of breast cancer research is vast and complex, this study helps to illuminate a path toward better treatments and a brighter future.

Date :
  1. Date Completed 2012-08-21
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21892704

DOI: Digital Object Identifier

NIHMS765193

Related Literature

Article Analysis
・Effects of letrozole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.